학술논문
PARIS and SPARTA: Finding the Achilles’ Heel of SARS-CoV-2
Document Type
article
Author
Simon, Viviana; Kota, Vamsi; Bloomquist, Ryan F; Hanley, Hannah B; Forgacs, David; Pahwa, Savita; Pallikkuth, Suresh; Miller, Loren G; Schaenman, Joanna; Yeaman, Michael R; Manthei, David; Wolf, Joshua; Gaur, Aditya H; Estepp, Jeremie H; Srivastava, Komal; Carreño, Juan Manuel; Cuevas, Frans; Ellebedy, Ali H; Gordon, Aubree; Valdez, Riccardo; Cobey, Sarah; Reed, Elaine F; Kolhe, Ravindra; Thomas, Paul G; Schultz-Cherry, Stacey; Ross, Ted M; Krammer, Florian
Source
mSphere. 7(3)
Subject
Language
Abstract
To understand reinfection rates and correlates of protection for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), we established eight different longitudinal cohorts in 2020 under the umbrella of the PARIS (Protection Associated with Rapid Immunity to SARS-CoV-2)/SPARTA (SARS SeroPrevalence And Respiratory Tract Assessment) studies. Here, we describe the PARIS/SPARTA cohorts, the harmonized assays and analysis that are performed across the cohorts, as well as case definitions for SARS-CoV-2 infection and reinfection that have been established by the team of PARIS/SPARTA investigators. IMPORTANCE Determining reinfection rates and correlates of protection against SARS-CoV-2 infection induced by both natural infection and vaccination is of high significance for the prevention and control of coronavirus disease 2019 (COVID-19). Furthermore, understanding reinfections or infection after vaccination and the role immune escape plays in these scenarios will inform the need for updates of the current SARS-CoV-2 vaccines and help update guidelines suitable for the postpandemic world.